Class Action Article

  • File A Talcum Powder Lawsuit: Talcum Powder Ovarian Cancer Lawsuits Talcum Powder Fallopian Tube Cancer Lawsuits Baby  Powder Ovarian Cancer Lawsuits Filed If you or a loved one used talcum powder products and were diagnosed with ovarian cancer, or fallopian tube can...

Class Action News

Drug Class Actions

  • Taxotere Lawyers for Permanent Hair Loss: Taxotere Baldness Lawyers For  Permanent Hair Loss Lawsuits Have you received Taxotere for breast cancer? Taxotere can result in hair loss or baldness  that is permanent. Taxotere  is a chemotherapy drug used for the treatment of breas...

Medical Device Lawsuits

  • Get A Hernia Mesh Lawyer | Hernia Mesh Lawsuits Filed: The hernia mesh lawyers of Class Action Lawyer Network are filing hernia mesh lawsuits for victims of a failed hernia mesh. We have Ethicon, Bard and Cook hernia mesh lawyers. Hernia Mesh Lawsuits Filed  For: Ethicon: Physiomesh Pro...

Posts Tagged ‘Januvia lawyers’

Lawyers For Drugs and Devices

Written by lisaspitzer on . Posted in ABG II Lawyers, ABG Modular Stem lawyers, Alabama Multidistrict Litigation Lawyers, Alaska Multidistrict Litigation Lawyers, Arizona Multidistrict Litigation Lawyers, Arkansas Multidistrict Litigation Lawyers, Asbestos, Baby Powder lawyer, Bair Hugger Surgical Blanket lawyer, Baltimore, Bard IVC Filter Lawyers, Blood Clot Filter lawyer, Boca Raton, Boston, California Multidistrict Litigation Lawyers, Charleston, Charlotte, Cincinnattti Talcum Powder lawyer, Colorado Multidistrict Litigation Lawyers, Dallas, Denver, DePuy Pinnacle Hip Replacement Updates, Detroit, File A Talcum Powder Lawsuit, Fort Lauderdale, Fort Lauderdale GranuFlo Lawyer, GranuFlo Dialysis Medication Lawyers, Granuflo Lawyer, Heartbuen medication lawyer, Heartburn Medication lawyer, Houston, Idaho Talcum Powder Lawyer, Infuse Bone Graft Lawywrs, Invokana Lawyers, Johnson and Johnson Baby Powder Lawsuit, Kansas Multidistrict Litigation Lawyers, Kentucky Multidistrict Litigation Lawyers, Little Rock Talcum Powder Lawyer, Los Angeles, Louisville, Macon, Maine Multidistrict Litigation Lawyers, Mass tort lawyer, Metronic Infuse Bone Graft Lawsuit, Miami, Minneapolis, NexGen Knee Replacement lawyers, NYC, NYC Class Action Lawyers, Philadelphia Amtrak Crash, Philadelphia Baby powder lawyer, Phoenix, Power Morcellator Lawyers, Provo, Raleigh-Durham, Risperdal Lawyers, Sarasota, Seattle, SSRI Birth Defects Lawyer, Stryker Hip replacement recall lawyer, Stryker Homedicam Rejuvinate, Stryker Rejuvinate, Stryker Rejuvinate Hip replacement recall lawyers, Talcum Powder cancer lawyers, Talcum Powder Ovarian cancer lawyer, Taxotere Lawyer, Toledo, Tylenol Liver Damage Lawsuits, West Palm Beach, Wisconsin Multidistrict Litigation Lawyers, Xarelto Lawyer, Xarelto Lawyers, Zimmer Knee Replacement lawyer

Lawyers For Drugs & Devices Our Class Action – Dangerous Drugs and Devices Lawyers are accepting cases for :

Abilify lawyers- excessive gambling, Bair Hugger Warming Blanket Lawyers, Benicar Lawyers, Biomet Hip Replacement, da Vinci Robotic Surgery, Depakote, DePuy Hip Replacement, DePuy Knee Replacement, GranuFlo lawyers, Hip Replacement lawyers, INFUSE Bone Graft lawyers, Invokana lawyers, IVC Filters lawyers, Januvia lawyers, NaturaLyte lawyers, Nexium lawyers- kidney failure, Power Morcellators, Talcum Powder ovarian cancer lawyers, Taxotere permanent baldness lawyers, Testosterone heart attack lawyers, Xarelto excessive bleeding lawyers, Zofran birth defect lawyers

About Filing A Dangerous Drugs or Devices Lawsuit

All dangerous drug and devices lawsuits have specific criteria for acceptance of your case. You must meet the criteria. many of these drug and devices lawsuits have been consolidated in a multi-district litigation. The judge has set the criteria for the lawsuit. You will be asked specific questions regarding your medical history, date you were implanted with the device or began using the medication, and if you are still using the medication or have had the device removed or revised in any way. Contact us to speak to an experienced drug and devices lawyer. These cases can be accepted for your local jurisdiction but, more often, they will be filed in the state where the lawsuits have been consolidated. These mass tort consolidated cases have a steering committee which is made up of selected lawyers and lead counsels. They are the only lawyers that  will litigate the cases. You do not need a local lawyer. Most lawyers whi accept these cases refer them to an experienced mass tort lawyer who is not local. You need an experienced mass tort lawyer.

Top Selling Drugs- Which Will Make It To An MDL Litigation

Written by lisaspitzer on . Posted in Drug Lawsuits, Drug Warnings, Drugs and Devices lawsuit attorneys

With new drugs coming out each month and many becoming best sellers we wonder which of these will start to implicate the manufacturer for lack of warnings for a medical condition.  We already know that Xarelto has lawsuits for excessive bleeding and Yaz just reached a settlement for causing blood clots and related medical conditions. According to Medscape Medical news the cholesterol-lowering drug rosuvastatin (Crestor, AstraZeneca) has been the  most prescribed branded drug in the United States, and the arthritis drug adalimumab (Humira, Abbott Laboratories) was the best-selling branded drug, according to the latest data from research firm IMS Health. Rosuvastatin had about 21 million prescriptions, followed by asthma medication fluticasone propionate/salmeterol (Advair Diskus, GlaxoSmithKline), at about 13.6 million prescriptions; the proton pump inhibitor esomeprazole (Nexium, AstraZeneca), at about 13.2 million prescriptions; the insulin glargine injection Lantus Solostar (sanofi-aventis), at about 11.2 million; and the attention-deficit drug lisdexamfetamine dimesylate (Vyvanse, Shire), at about 10.6 million. Rounding out the top 10 most prescribed drugs for the period (in order) were the antiepileptic drug pregabalin (Lyrica, Pfizer), the chronic obstructive pulmonary disease medication tiotropium bromide (Spiriva Handihaler, Boehringer Ingelheim Pharmaceuticals), the diabetes drug sitagliptin (Januvia, Merck), the asthma/chronic obstructive pulmonary disease drug budesonide/formoterol (Symbicort, AstraZeneca), and the antipsychotic medication aripiprazole (Abilify, Otsuka Pharmaceutical). Top Sellers The top seller, arthritis drug adalimumab (Humira, Abbott Laboratories), had sales of about $8.6 billion, followed by the antipsychotic aripiprazole (Abilify, Otsuka Pharmaceutical), at $7.2 billion; the arthritis drug etanercept (Enbrel, Amgen), at roughly $6.1 billion; the cholesterol drug rosuvastatin (Crestor, AstraZeneca), at just under $6.1 billion; and the insulin glargine injection Lantus Solostar (sanofi-aventis), at around $5 billion. The remaining top 10 drugs in sales were the hepatitis C drug sofosbuvir (Sovaldi, Gilead Sciences), at $4.9 billion; the asthma drug fluticasone propionate/salmeterol (Advair Diskus, GlaxoSmithKline), at $4.8 billion; the proton pump inhibitor esomeprazole (Nexium, AstraZeneca), at $4.7 billion; the diabetes drug sitagliptin (Januvia, Merck), at $3.8 billion; and the antiepileptic pregabalin (Lyrica, Pfizer), at $3.4 billion. Top 100 Brands by Sales Product Sales, $ Humira $8,566,451,647 Abilify $7,238,451,779 Current lawsuits by Abilify lawyers Enbrel $6,139,812,530 Crestor $6,090,223,570 Lantus Solostar $5,023,092,599 Sovaldi $4,925,098,469 Advair Diskus $4,769,250,836 Nexium $4,709,542,900 Januvia $3,792,531,657  Current lawsuits pending Lyrica $3,442,755,962 Spiriva Handihaler $3,388,442,306 Symbicort $2,480,108,204 Xarelto $2,460,606,162 Current lawsuits pending Vyvanse $2,255,494,506 Novolog Flexpen $2,212,204,664 Zetia $2,155,848,498 Stelara $1,781,288,922 Prevnar $1,746,605,006 Humalog Kwikpen $1,588,639,456 Gilenya $1,577,027,870 Cialis $1,520,551,442 Restasis $1,410,652,178 Latuda $1,379,675,847 Viagra $1,375,305,952 Recent lawsuits  for Melanoma Seroquel XR $1,359,121,073 Celebrex $1,323,059,229 Invokana $1,254,451,641 Orencia $1,188,411,778 Androgel $1,182,514,119 Current lawsuits pending Nasonex $1,124,061,350 Tamiflu $1,050,683,805 Vesicare $1,040,724,740 Eliquis $964,121,283 Cimzia $933,953,154 Namenda XR $857,157,299 Levemir $851,149,040 Pradaxa $850,313,699 Current lawsuits pending- Pradaxa lawyers Prolia $817,906,368 Pristiq $750,241,124 Nuvaring $690,996,076 Nuvaring lawyers Zostavax $686,790,521 Dulera $669,637,717 Gardasil $659,747,125 Exelon $647,136,515 Simponi $608,898,230 Mirena $603,038,710 Lawsuits and MDL- Mirena IUD Lawyers Onglyza $579,325,631 Linzess $515,749,802 Premarin $493,812,315 Intuniv $489,285,664 Chantix $472,869,473 Avodart $471,499,125 Xeljanz $413,374,592 Uloric $411,824,301 Farxiga $410,997,209 Myrbetriq $408,957,063 Premarin Vaginal $397,570,841 Epipen Jr 2-Pak $389,528,868 Vimovo $368,883,419 Epiduo $349,457,182 Relpax $331,629,578 Nexplanon $301,889,830 Aczone $278,671,485 Lovaza $259,812,629 Lipitor $251,981,518 Axiron $233,871,526 Cymbalta $223,291,761 Toviaz $219,986,729 Livalo $185,479,248 Jublia $178,047,175 Actonel $152,123,935 Breo Ellipta $140,349,328 Flumist $131,614,245 Xiaflex $127,063,110 Quillivant XR $107,092,690 Belviq $96,038,704 Aciphex $91,853,217 Latisse $82,671,844 Lunesta $79,894,370 Singulair $78,256,791 Niaspan $71,761,121 Estring $71,006,566 Anoro Ellipta $64,460,164 Plavix $52,762,015 Botox $51,501,869 Yaz-28 $49,432,035 Yas lawyers- settlement just announced Osphena $49,034,121 Ambien CR $45,955,805 Aricept $26,773,067 Brisdelle $22,581,016 Omnaris $19,352,785 Flomax $18,139,072 Trilipix $16,459,450 Boniva $16,056,457 Boniva lawyers filing lawsuits Caduet $14,166,476 Duavee $13,567,296 Reclast $11,208,523 Lawsuits being filed Seasonique $11,101,960 Botox Cosmetic $952,021 Victoza Unsp N-N Grand total $112,494,804,575 article courtesy of Medscape Medical News © 2015 WebMD, LLC        

Januvia Lawyers Accepting Pancreatic Cancer Lawsuits

Written by lisaspitzer on . Posted in Class MDL Class Action News

Januvia and Janumel Lawsuit Lawyers Update  MDL Formed

This is good news for patients on these medications  who are at risk for pancreas cancer.

The manufacturer of the drugs has agreed to move a growing number of injury claims to a special federal court in California*.

The resource center contains information on Januvia and Janumet, which are pill-form diabetes medications sold by Merck to help those with type-2 diabetes control blood sugar. Last year, they were two of the best-selling drugs for the company, with sales of over $5 billion**.

Research suggesting the drugs may be linked to cancer:

A 2011 study from UCLA indicated the drug could increase the risk of pancreatic cancer by 172% and thyroid cancer by 48%***. The Journal for the American Medical Association also recently warned Januvia could double the risk of pancreatitis, a major risk factor for pancreatic cancer****.

Due to the rising number of patients filing a Januvia lawsuit alleging cancer, lawyers have requested that cases be consolidated to a special federal multi-district court in California. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

If you or a loved one is on these medications an has been diagnosed with pancreas cancer contact our Januvia lawyers today.

Pancreatic Cancer Lawsuits For Januvia, Janumet, Byetta, Victoza

Written by lisaspitzer on . Posted in Drug Lawsuits

 Merck Supports MDL For Januvia, Janumet Lawsuits Over Pancreatic Cancer. Class Action Lawyer Network lawyers for Januvia, Janumet, Byetta and Victoza are filing pancreatic cancer lawsuits for diabetic victims of these medications.

Posted: 30 Apr 2013 08:25 AM PDT

Following a request filed by plaintiffs earlier this month to establish a federal MDL for all pancreatic cancer lawsuits involving the diabetes drugs Januvia, Janumet, Byetta and Victoza, Merck has indicated that it agrees cases involving their products should be included in any consolidated proceedings established.

In a response (PDF) filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) on April 29, Merck said that it agrees that all Januvia lawsuits and Janumet lawsuits filed in the federal court systems should be centralized before one judge for coordinated handling, as part of an MDL or multidistrict litigation.

Further, the drug maker indicates that it agrees that it is appropriate to include cases involving other diabetes drugs that are part of a class of medications, known as incretin mimetics, in the same MDL.

Merck manufactures Januvia (sitagliptin) and Janumet, which combines Januvia with the older diabetes drug metformin. The drug maker faces a growing number of lawsuits filed by former users of the medications who indicate that they developed pancreatic cancer from side effects of Januvia or Janumet, alleging that Merck failed to provide adequate warnings for consumers or the medical community.

A number of similar Byetta lawsuits and Victoza lawsuits have also been filed by former users of those competing diabetes drugs who have been diagnosed with pancreatic cancer. Many complaints also allege that the plaintiffs used a combination of the various different drugs over a number of years.

Diabetes Drug Pancreatic Cancer Risk

Incretin mimetics are a relatively new class of diabetes drug, which work by mimicking the incretin hormones that the body usually produces to naturally stimulate th release of insulin in response to a meal.

Byetta (exenatide) was the first member of this class approved by the FDA, introduced by Amylin Pharmaceuticals and Eli Lilly in 2005, as a twice daily injection. Januvia was introduced by Merck the following year as an oral medication, and a combination pill containing Januvia and the combination medication that includes metformin was introduced in 2007, under the brand name Janumet. Victoza (liraglutide) was introduced by Novo Nordisk in 2010 as a daily injection.

The medications are widely used among individuals with type 2 diabetes, generating billions in annual sales. Januvia and Janumet are among the best selling medications for the global pharmaceutical company Merck, with Janumet sales reaching over $1.3 billion in 2011 and Januvia sales hitting $919 million during the first quarter of 2012 alone. Byetta sales were reported at $710 million in 2010 and were expected to reach $1 billion by 2015. Likewise, Victoza sales were about $1 billion in 2011, and reached $748 million during the first half of 2012.

In recent months, concerns have emerged about the potential risk of pancreatic cancer from Byetta, Januvia, Janumet and Victoza. The medications have previously been linked to a risk of pancreatitis, which can lead to the development of pancreatic cancer.

Last month, the FDA launched an investigation into the potential incretin mimetics pancreatic cancer risk. The safety review was initiated after results of a recent study identified pre-cancerous cellular changes in pancreatic tissue taken from individuals treated with one of the drugs. European health officials have also launched a similar review.
Pancreatic Cancer Litigation Over Januvia, Janumet, Byetta and Victoza

As of the beginning of this month, at least 53 product liability lawsuits were pending in seven different U.S. District Courts alleging that Januvia, Janumet, Byetta and/or Victoza caused former users to develop pancreatic cancer. Lawyers investigating additional cases have also suggested that the number of complaints is expected to increase dramatically in the coming months.

On April 5, a group of plaintiffs filed a request to centralize the incretin mimetic pancreatic cancer litigation, indicating that all cases filed throughout the federal court system against Merck, Novo Nordisk (the manufacturer of Victoza) or Amylin Pharmaceuticals and Eli Lilly (the makers of Byetta) should be consolidated before U.S. District Judge Anthony Battaglia in the Southern District of California.

Such consolidation is designed to reduce duplicative discovery among a large number of cases, avoid conflicting rulings from different judges and to serve the convenience of the witnesses, parties and the courts. In the original motion, plaintiffs argued that there are sufficient overlapping common issues of fact and law to justify combining the cases against the different drug makers before one judge.

Responses from the manufacturer were due this week. As of the end of the day Monday, only Merck and Novo Nordisk had filed responses. Both drug makers indicated that they support the centralization of the litigation and agree that all cases involving pancreatic cancer from incretin mimetic diabetes drugs should be included in the same MDL. A response from Amylin and Eli Lilly was not yet available.

Both Merck and Novo Nordisk said the MDL should be limited to cases involving pancreatic cancer, as some users of the drugs have also reported severe pancreatitis and thyroid cancer as well. Both companies also agree that the Southern District of California is the best venue for the litigation.

The U.S. JPML is expected to schedule oral arguments on the motion at an upcoming hearing session on July 25 in Portland, Maine.

If you or a loved on has gotten pancreatic cancer from any of the mentioned medications call now for a  MDL lawyer.